» Articles » PMID: 32601132

MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age

Overview
Specialty General Medicine
Date 2020 Jul 1
PMID 32601132
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in members of the mitogen-activated protein kinase (MAPK) pathway are extensively studied in epithelial malignancies, with mutations being one of the most common alterations activating this pathway. However, mutations are overall quite rare in hematological malignancies. Studies over the past decade have identified high-frequency , , and other kinase alterations in two groups of MAPK-driven hematopoietic neoplasms: hairy cell leukemia (HCL) and the systemic histiocytoses. Despite HCL and histiocytoses sharing common molecular alterations, these are phenotypically distinct malignancies that differ in respect to clinical presentation and suspected cell of origin. The purpose of this review is to highlight the molecular advancements over the last decade in the histiocytic neoplasms and HCL and discuss the impact these insights have had on our understanding of the molecular pathophysiology, cellular origins, and therapy of these enigmatic diseases as well as perspectives for future research directions.

Citing Articles

Langerhans Cell Histiocytosis and Other Histiocytic Lesions.

McKinney R, Wang G Head Neck Pathol. 2025; 19(1):26.

PMID: 39998733 PMC: 11861498. DOI: 10.1007/s12105-025-01766-2.


The anti-leukemia activity and mechanisms of shikonin: a mini review.

Dong H, Chang C, Gao F, Zhang N, Yan X, Wu X Front Pharmacol. 2023; 14:1271252.

PMID: 38026987 PMC: 10651754. DOI: 10.3389/fphar.2023.1271252.


Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis.

Milne P, Bomken S, Slater O, Kumar A, Nelson A, Roy S Blood Adv. 2022; 7(10):2171-2176.

PMID: 36112425 PMC: 10196915. DOI: 10.1182/bloodadvances.2021006732.


Genomic profiling for clinical decision making in lymphoid neoplasms.

de Leval L, Alizadeh A, Bergsagel P, Campo E, Davies A, Dogan A Blood. 2022; 140(21):2193-2227.

PMID: 36001803 PMC: 9837456. DOI: 10.1182/blood.2022015854.


Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.

Avery T, Kohler N, Zeiser R, Brummer T, Ruess D Front Oncol. 2022; 12:931774.

PMID: 35965494 PMC: 9363660. DOI: 10.3389/fonc.2022.931774.


References
1.
Maitre E, Cornet E, Troussard X . Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94(12):1413-1422. DOI: 10.1002/ajh.25653. View

2.
Waterfall J, Arons E, Walker R, Pineda M, Roth L, Killian J . High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2013; 46(1):8-10. PMC: 3905739. DOI: 10.1038/ng.2828. View

3.
NEZELOF C, Basset F . From histiocytosis X to Langerhans cell histiocytosis: a personal account. Int J Surg Pathol. 2001; 9(2):137-46. DOI: 10.1177/106689690100900208. View

4.
Sumegi J, Streblow R, Frayer R, Dal Cin P, Rosenberg A, Meloni-Ehrig A . Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2009; 49(3):224-36. PMC: 2808450. DOI: 10.1002/gcc.20731. View

5.
Wood G, Hu C, Beckstead J, Turner R, Winkelmann R . The indeterminate cell proliferative disorder: report of a case manifesting as an unusual cutaneous histiocytosis. J Dermatol Surg Oncol. 1985; 11(11):1111-9. DOI: 10.1111/j.1524-4725.1985.tb01399.x. View